Japan con­sid­ers ad­just­ing clin­i­cal tri­al re­quire­ments to re­move the need for lo­cal stud­ies — re­port

Japan is re­think­ing its clin­i­cal tri­al re­quire­ments to ad­dress a lag in Japan­ese ap­provals for new drugs that are al­ready avail­able in oth­er coun­tries, ac­cord­ing to the fi­nan­cial news out­let Nikkei.

In the next few months, the coun­try is ex­pect­ed to lift a rule re­quir­ing ad­di­tion­al safe­ty stud­ies with Japan­ese par­tic­i­pants be­fore a drug can be mar­ket­ed, Nikkei re­port­ed, cit­ing un­named sources.

Japan has been grap­pling with a so-called “drug lag” for decades, in which drugs ap­proved in the US and Eu­rope can take much longer to ar­rive on the Japan­ese mar­ket for a num­ber of rea­sons, in­clud­ing clin­i­cal tri­al re­quire­ments.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER